| Patient | Paul Robeson |
|---|---|
| Date of birth | 1898-04-09 |
| Identifiers | MRN HR-ML048-SYN-TD; SSN (made up) 000-48-2647 |
| Document date | 2026-11-01 |
| Author | Theodore Bankole-Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for three months of low mood, exhaustion, poor sleep and withdrawal: depression screening, safety assessment and safety plan, tests for medical causes, and urgent psychiatric consultation. Concerns: He is exhausted, sleeps poorly and has lost the wish to sing, and wants to know what is wrong; He worries that a psychiatric record could be used against him by the people who have taken his passport and his work; He wants to keep working for civil rights and to sing again. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg tablet, one tablet each morning | 50 mg each morning for two weeks | Oral route | 1957-03-12 to 1957-03-25 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning | 100 mg each morning | Oral route | 1957-03-26 to 1957-04-19 | completed | S |
| Sertraline 50 mg tablets, three tablets (150 mg) each morning | 150 mg each morning for two weeks | Oral route | 1957-04-20 to 1957-05-03 | completed | S |
| Sertraline 100 mg tablets, two tablets (200 mg) each morning | 200 mg each morning | Oral route | 1957-05-04 to 1957-06-07 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning for one week, then stop | 100 mg each morning for one week during the switch | Oral route | 1957-06-08 to 1957-06-14 | completed | S |
| Venlafaxine extended-release 75 mg capsule, one capsule each morning with food | 75 mg each morning for one week | Oral route | 1957-06-08 to 1957-06-14 | completed | S |
| Venlafaxine extended-release 150 mg capsule, one capsule each morning with food | 150 mg each morning for three weeks | Oral route | 1957-06-15 to 1957-07-05 | completed | S |
| Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food | 225 mg each morning; 30-day supply at a time | Oral route | 1957-07-06 | active | S |
| Aripiprazole 2 mg tablet, one tablet each morning | 2 mg each morning for two weeks | Oral route | 1957-08-24 to 1957-09-06 | completed | S |
| Aripiprazole 5 mg tablet, one tablet each morning | 5 mg each morning | Oral route | 1957-09-07 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Advance care planning conversation, about 20 minutes | 1957-10-05 to 1957-10-05 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1957-10-05 | Influenza vaccine, inactivated, trivalent, preservative-free | completed | S |
| 1957-10-05 | Pneumococcal conjugate vaccine, 20-valent (PCV20) | completed | S |
| 1957-10-05 | Zoster vaccine, recombinant, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1955 | Prostate surgery; reason not recorded in the cited source | D (CLM-0008) |
| 1955 | A breakdown described by his biographer as a period of intense, driven energy followed by a deep depression | D (CLM-0008) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He is exhausted, sleeps poorly and has lost the wish to sing, and wants to know what is wrong | active | S |
| He worries that a psychiatric record could be used against him by the people who have taken his passport and his work | active | S |
| He wants to keep working for civil rights and to sing again | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.2 on 1957-03-09; Leukocytes [#/volume] in Blood by Automated count 6.1 on 1957-03-09; Platelets [#/volume] in Blood by Automated count 240 on 1957-03-09; Sodium [Moles/volume] in Serum or Plasma 136 on 1957-08-24; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1957-03-09; Creatinine [Mass/volume] in Serum or Plasma 1.05 on 1957-03-09; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M 82 on 1957-03-09; Glucose [Mass/volume] in Serum or Plasma 94 on 1957-08-24; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1957-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1957-03-09; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 420 on 1957-03-09; Folate [Mass/volume] in Serum or Plasma 9.5 on 1957-03-09; Testosterone [Mass/volume] in Serum or Plasma 420 on 1957-03-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 1957-08-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1957-10-05; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 12 on 1957-03-09; Total score [AUDIT-C] 1 on 1957-03-09; Total score [MoCA] 28 on 1957-08-24; Cholesterol [Mass/volume] in Serum or Plasma 204 on 1957-08-24; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 1957-08-24; Triglyceride [Mass/volume] in Serum or Plasma 130 on 1957-08-24; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 132 on 1957-08-24 [S]
Strengths and supports: Supports he names: his music and the spirituals he grew up with, his work for civil rights, and old friends from the stage and the movement [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arranged | resolved | confirmed | R53.83 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D). |
| Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview) | active | confirmed | F33.2 | S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted. |
| Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusion | active | confirmed | Z60.5 | S — Synthetic coding of his documented persecution as a social determinant of his depression. |
| Acute bronchitis after a cold, without signs of pneumonia; treated without antibiotics and without dextromethorphan or decongestants because of venlafaxine; resolved | resolved | confirmed | J20.9 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1957-03-09 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 1957-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1957-03-09 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1957-03-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1957-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.05 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1957-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1957-03-09 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1957-03-09 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1957-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 1957-03-09 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 420 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1957-03-09 | Folate [Mass/volume] in Serum or Plasma | 9.5 | ng/mL | >=3 ng/mL | Normal | S |
| 1957-03-09 | Testosterone [Mass/volume] in Serum or Plasma | 420 | ng/dL | 264-916 ng/dL | Normal | S |
| 1957-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 1957-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 22 | {score} | S | ||
| 1957-03-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 12 | {score} | S | ||
| 1957-03-09 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 1957-03-09 | Total score [MoCA] | 28 | {score} | S | ||
| 1957-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 19 | {score} | S | ||
| 1957-06-08 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 17 | {score} | S | ||
| 1957-08-24 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-08-24 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1957-08-24 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 1957-08-24 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 1957-08-24 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 1957-08-24 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 1957-08-24 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=129 mg/dL | High | S |
| 1957-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 1957-08-24 | Total score [MoCA] | 28 | {score} | S | ||
| 1957-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1957-03-09 | Body height | 190 | cm | S |
| 1957-03-09 | Body weight | 99 | kg | S |
| 1957-03-09 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 1957-03-09 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1957-03-09 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1957-03-09 | Heart rate | 76 | /min | S |
| 1957-03-09 | Respiratory rate | 14 | /min | S |
| 1957-03-09 | Body temperature | 36.7 | Cel | S |
| 1957-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1957-03-12 | Body height | 190 | cm | S |
| 1957-03-12 | Body weight | 98.8 | kg | S |
| 1957-03-12 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 1957-03-12 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1957-03-12 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1957-03-12 | Heart rate | 74 | /min | S |
| 1957-03-12 | Respiratory rate | 14 | /min | S |
| 1957-03-12 | Body temperature | 36.6 | Cel | S |
| 1957-03-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1957-04-20 | Body height | 190 | cm | S |
| 1957-04-20 | Body weight | 99.5 | kg | S |
| 1957-04-20 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 1957-04-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1957-04-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1957-04-20 | Heart rate | 72 | /min | S |
| 1957-04-20 | Respiratory rate | 14 | /min | S |
| 1957-04-20 | Body temperature | 36.7 | Cel | S |
| 1957-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1957-06-08 | Body height | 190 | cm | S |
| 1957-06-08 | Body weight | 100.2 | kg | S |
| 1957-06-08 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1957-06-08 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1957-06-08 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1957-06-08 | Heart rate | 74 | /min | S |
| 1957-06-08 | Respiratory rate | 14 | /min | S |
| 1957-06-08 | Body temperature | 36.6 | Cel | S |
| 1957-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1957-08-24 | Body height | 190 | cm | S |
| 1957-08-24 | Body weight | 101 | kg | S |
| 1957-08-24 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 1957-08-24 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1957-08-24 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1957-08-24 | Heart rate | 78 | /min | S |
| 1957-08-24 | Respiratory rate | 14 | /min | S |
| 1957-08-24 | Body temperature | 36.6 | Cel | S |
| 1957-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1957-07-27 | Body height | 190 | cm | S |
| 1957-07-27 | Body weight | 100.6 | kg | S |
| 1957-07-27 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 1957-07-27 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1957-07-27 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1957-07-27 | Heart rate | 84 | /min | S |
| 1957-07-27 | Respiratory rate | 16 | /min | S |
| 1957-07-27 | Body temperature | 37.4 | Cel | S |
| 1957-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1957-10-05 | Body height | 190 | cm | S |
| 1957-10-05 | Body weight | 102.4 | kg | S |
| 1957-10-05 | Body mass index (BMI) [Ratio] | 28.4 | kg/m2 | S |
| 1957-10-05 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1957-10-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1957-10-05 | Heart rate | 72 | /min | S |
| 1957-10-05 | Respiratory rate | 14 | /min | S |
| 1957-10-05 | Body temperature | 36.6 | Cel | S |
| 1957-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1957-03-09 | New patient visit for three months of low mood, exhaustion, poor sleep and withdrawal: depression screening, safety assessment and safety plan, tests for medical causes, and urgent psychiatric consultation | finished | S |
| 1957-03-12 | Psychiatric consultation and review: diagnosis of recurrent major depression, bipolar screening, start of sertraline and behavioral activation | finished | S |
| 1957-04-20 | Six-week review: minimal response; sertraline increased | finished | S |
| 1957-06-08 | Three-month review: no response to an adequate sertraline trial; switch to venlafaxine | finished | S |
| 1957-08-24 | Twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECT | finished | S |
| 1957-07-27 | Same-day sick visit for acute bronchitis on venlafaxine | finished | S |
| 1957-10-05 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Evaluation: PHQ-9, GAD-7, AUDIT-C and a cognitive screen (MoCA); blood count, metabolic panel, calcium, TSH, vitamin B12, folate, morning testosterone and hemoglobin A1c, with HIV and syphilis tests, to exclude medical causes; a review of medicines; and a sleep apnea screen | completed | GL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-CMID-2026 | S |
| Urgent psychiatric consultation in three days to confirm the diagnosis with a structured interview, screen for bipolar disorder, judge suicide risk and the level of care, and advise on psychotherapy, medicines, and when ECT or other treatments would be indicated | completed | GL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-APA-ECT-2001 | S |
| Safety: structured suicide-risk assessment, a written safety plan, no firearm in the home, medicines dispensed in limited supplies and kept locked, the 988 Suicide & Crisis Lifeline, and a safety review at every visit | completed | GL-SUICIDE-2024, GL-VADOD-MDD-2022 | S |
| Trust and equity: explain who can see his record and how it is protected; a therapist of his choosing, including a Black clinician if he wishes; treat discrimination and persecution as real stressors and record his account of surveillance as realistic; a social worker for help with income and costs; guard against the documented under-treatment of depression in Black patients by measuring response at every visit | completed | GL-WILLIAMS-2007, GL-DISPARITY-2014, GL-SPRENGER-2025, GL-APA-DEP-2019 | S |
| Treatment: behavioral activation weekly with a psychologist for about sixteen sessions, then CBT if needed; sertraline 50 mg, raised to 100 mg at two weeks and to 200 mg by eight weeks as tolerated; PHQ-9 at every visit with response defined as a 50 percent fall and remission as a score below 5; sodium at about six weeks; switch to an SNRI if the PHQ-9 falls by less than a quarter after an adequate trial, and consider augmentation, ECT, rTMS or esketamine if a second adequate trial brings only a partial response; watch for hypomania after starting an antidepressant | completed | GL-APA-DEP-2019, GL-VADOD-MDD-2022, GL-CMID-2026 | S |
| Switch to venlafaxine extended-release by cross-taper: venlafaxine 75 mg for a week while sertraline is halved, then 150 mg for three weeks and 225 mg; blood pressure at every visit; 30-day supplies because venlafaxine is more dangerous in overdose | completed | GL-VADOD-MDD-2022, GL-APA-DEP-2019 | S |
| Treatment-resistant depression: aripiprazole 2 mg, raised to 5 mg at two weeks, with weight at four, eight and twelve weeks, A1c and lipids at baseline and twelve weeks, and an abnormal involuntary movement examination at baseline and six months; an informed consent discussion about ECT (general anesthesia with a muscle relaxant, right unilateral ultrabrief pulse, two or three treatments a week in a defined course, cognitive testing before and during the course, and the right to stop at any time), with rTMS and esketamine as alternatives; ECT not started now and offered if augmentation fails or if he becomes unable to eat or drink, psychotic or acutely suicidal | completed | GL-VADOD-MDD-2022, GL-APA-DEP-2019, GL-APA-ECT-2001, GL-APA-ECT-2024, GL-SPRENGER-2025, GL-CMID-2026 | S |
| Acute bronchitis: no antibiotic and no chest X-ray with normal vital signs and a normal chest examination; honey, warm drinks and steam; plain guaifenesin if needed; no dextromethorphan, which with venlafaxine can cause serotonin syndrome, and no pseudoephedrine or phenylephrine, which raise blood pressure further on venlafaxine; check labels of combination cold remedies; return for fever, breathlessness, chest pain or a cough lasting more than three weeks | completed | GL-ARTI-2016, GL-VADOD-MDD-2022 | S |
| Prevention: stool FIT kit for colorectal screening; the earlier prostate surgery records obtained before any decision on PSA testing; a ten-year cardiovascular risk of about 9 percent discussed, with his choice of diet and activity first and a statin to be reconsidered in a year; hepatitis B and C screening; influenza, PCV20 and the first recombinant zoster dose today, the second zoster dose in two to six months | completed | GL-USPSTF-CRC-2021, GL-USPSTF-PROS-2018, GL-USPSTF-STATIN-2022, GL-CDC-IMZ-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Response to treatment: PHQ-9 down by at least half from 22 | 1957-10-05 | completed | PHQ-9 6 at about seven months, a 73 percent fall | S |
| Remission: PHQ-9 below 5 | 1957-10-05 | active | Not yet met: PHQ-9 6 six weeks after augmentation; continuing | S |
| Stay safe: safety plan in place and reviewed at every visit, with no self-harm | 1957-10-05 | active | Met so far: no thoughts of suicide since the first months; safety plan reviewed at every visit | S |
| Sing again: daily vocal practice and one public engagement a month | 1957-10-05 | completed | Daily practice resumed; sang at two community gatherings in the past month | S |
| Sleep six to seven hours a night | 1957-10-05 | completed | About six and a half hours a night | S |
Structured synthetic safety assessment on 1957-03-09: current ideation present, intent absent, plan absent. Outpatient care with a psychiatric consultation in three days and close follow-up. C-SSRS screen: wish to be dead on several days in the past month; no active thoughts of suicide, intent, plan, preparation or past attempt. Risk factors reviewed: severe depression, an older man, insomnia, loss of work and income, isolation, and sustained persecution. Means counseling: there is no firearm in the home and he will not acquire one; medicines will be dispensed in limited supplies and kept in a locked box. A written safety plan was made with him, with warning signs, coping steps, people and places for distraction, and crisis numbers; the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]